Alpine Immune Sciences, Inc.

ALPN

US02083G1004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
64.97 ^USD	+0.02%		-.--%	+240.87%

05-20	Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index	CI
05-20	Vertex Pharmaceuticals Incorporated completed the acquisition of Alpine Immune Sciences, Inc. from a group of shareholders.	CI

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P Biotechnology Select Industry Index

May 19, 2024

Latest news about Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index	05-19	CI
Vertex Pharmaceuticals Incorporated completed the acquisition of Alpine Immune Sciences, Inc. from a group of shareholders.	05-19	CI
Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P TMI Index	05-19	CI
Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P Biotechnology Select Industry Index	05-19	CI
Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P Global BMI Index	05-19	CI
Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Biotechnology Index	05-16	CI
Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone	05-10	MT
Alpine Immune Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
MOVES -Lazard hires veteran healthcare dealmaker Colocci as vice chairman	05-09	RE
Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug	05-06	DJ
North American Morning Briefing : Stock Futures -2-	04-17	DJ
TD Cowen Downgrades Alpine Immune Sciences to Hold From Buy	04-16	MT
North American Morning Briefing : Stock Futures -2-	04-15	DJ
Leerink Partners Downgrades Alpine Immune Sciences to Market Perform From Outperform	04-12	MT
North American Morning Briefing : Big Banks Kick -2-	04-12	DJ
Health Care Slips on Risk Bias -- Health Care Roundup	04-11	DJ
Wall Street rebounds on softer inflation data, eyes on earnings	04-11	RE
Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...	04-11
Wolfe Research Downgrades Alpine Immune Sciences to Peer Perform From Outperform	04-11	MT
Sector Update: Health Care Stocks Steady Pre-Bell Thursday	04-11	MT
Will there be any Fed rate cuts this year?	04-11
Nasdaq set for higher open as fresh inflation data allays rate jitters	04-11	RE
Wholesale Prices Rise Less Than Expected in March as US Equity Futures Waver Pre-Bell	04-11	MT
Sector Update: Health Care	04-11	MT
HC Wainwright Downgrades Alpine Immune Sciences to Neutral From Buy, Raises Price Target to $65 From $50	04-11	MT

Chart Alpine Immune Sciences, Inc.

Duration

Period

More charts

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Companyâs approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation, inducing ligand (APRIL), cytokines, which play key roles in the pathogenesis of multiple autoimmune diseases via their contribution to the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Its ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator (ICOS), and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Alpine Immune Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALPINE IMMUNE SCIENCES, INC.	+240.87%	4.46B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B
INSMED INCORPORATED	+77.64%	8.87B

Bio Therapeutic Drugs